In this context, imatinib mesylate (Gleevec), which exerts inhibitory activity against the signaling cascade activated by CD117 (27), has been used against gastrointestinal stromal tumors (GIST) and metastatic melanoma with c-Kit mutations (28, 29). The gene discussed is KIT; the disease is gastrointestinal stromal tumor.